

# Scientific Report 2016



**Josep Carreras<sup>9</sup>**  
LEUKAEMIA  
Research Institute

### **Headquarters**

C/ Muntaner, 383 3r. 08021 Barcelona  
Tel. (+34) 93 414 55 66

For any matter concerning this report  
please contact:

[comunicacio@carrerasresearch.org](mailto:comunicacio@carrerasresearch.org)

The report can also be downloaded  
from: <http://www.carrerasresearch.org>

### **Publisher, layout and typesetting**

Josep Carreras Leukaemia Research  
Institute

### **Photography**

Photographic archives of the Josep  
Carreras Leukaemia Foundation and  
the Josep Carreras Leukaemia  
Research Institute



“The Institute's three campuses are surrounded by excellent scientific and health service facilities. It is the aim of our project to enhance, integrate, share and strengthen this already excellent situation even more, and this is already being done at the management level, by simplifying and sharing structures, and at the scientific level, by integrating cross-section and multi-site services to avoid unnecessary duplication. Everything we do is focused on making leukaemia and other malignant blood diseases 100% curable one day.”

**Josep Carreras**

President of the Board of Trustees  
Josep Carreras Leukaemia Research Institute  
(IJC)



# Contents

---

## About us

Welcome  
Who we are  
Mission, vision and values

## Our team

Governing bodies  
Organisational chart  
Human resources

## Financial data

Income statement  
Balance sheet  
Fundraising

---

## Scientific activities

Research groups  
Research projects  
Technology platforms  
Clinical trials  
Innovation and  
transferability

## Scientific production

Publications  
Impact factors

## Training activities

Graduate and post-  
graduate  
Theses read  
Seminars and sessions  
Courses and congresses

---

## Cooperation

Agreements  
Institutions involved

## Communication

Scientific dissemination  
Institutional events

## Upcoming challenges

Opening of the IJC  
Badalona  
Strategic Plan 2018-2022



# About us

# Welcome

Behind all research there is a patient, a relation, a person, a team, a community, a hospital, a research centre, an organisation, a patron...

## **Together we are unstoppable against leukaemia!**

Once again the IJC's annual report is testimony to the excellent research being carried out at the three Josep Carreras campuses. Our congratulations are due, therefore, to everyone for their magnificent work and scientific rigour.

2016 was a year in which progress was made in the fight against leukaemia. It was a year of combined scientific efforts, continuing cooperation and commitment to society.

And our centre has seen the expansion of its facilities come true with the opening of the new building in Badalona, made possible by funding from the Josep Carreras Foundation.



Notable aspects of the IJC's management and leadership were the approval of the integrating SUMA project between the Germans Trias Institute (IGTP) and the Institute for Predictive and Personalised Cancer Medicine (IMPPC), the incorporation of new research groups, and the acquisition of new technological equipment.

Similarly notable has been the ability to synchronise research, health care, innovation and teaching, something of fundamental importance for achieving scientific excellence.

With all this in mind, it is our pleasure to invite you to learn more from the following pages about the activities in 2016, activities which have earned this centre a leading position in biomedical research to confront leukaemia.

Evarist Feliu  
President of the Delegate Committee of the  
Josep Carreras Leukaemia Research Institute

# Who we are

## Three campuses united to win the battle against leukaemia and other malignant blood diseases



The Josep Carreras Leukaemia Research Institute (IJC), a Generalitat de Catalunya Research Centre (CERCA), was established with the aim of promoting biomedical research into, and the development of, personalised medicine in the field of malignant blood diseases, especially leukaemia. It is a centre without precedent which, with the work and dedication of researchers from around the world, uses the most innovative technologies to try to vanquish leukaemia and other malignant blood diseases.

The IJC has three independent and coordinated scientific campuses: the Hospital Clínic-UB Campus, located at the research facilities of Barcelona's Hospital Clínic, and those of the University of Barcelona (UB) Faculty of Medicine, coordinated by Dr. Álvaro Urbano Ispizua, under the research direction of Dr. Pablo Menéndez; the Catalan Institute of Oncology/Germans Trias i Pujol Campus in Badalona, located near the Germans Trias i Pujol University Hospital and its research foundation and the Autonomous University of Barcelona (UAB) Germans Trias i Pujol Teaching Unit. The ICO-Germans Trias i Pujol Campus is coordinated by Dr. Evarist Feliu and the Research Director is Dr. Francesc Solé. The third campus is the Sant Pau Campus and its research foundation, located within the health care facilities of the Hospital de la Santa Creu i Sant Pau and the UAB's Sant Pau teaching unit, coordinated by Dr. Jordi Sierra.

The IJC's Hospital Clínic-UB Campus reaffirms the UB Faculty of Medicine and the Hospital Clínic's scientific commitment to excellence in the field of hematology, which commenced with the work of Prof. Farreras Valentí and which has been able to continue thanks to the extraordinary work carried out by Prof. Ciril Rozman and those who studied under him.



# Mission

The Josep Carreras Leukaemia Research Institute's mission is to carry out research into the basic, epidemiological, preventive, clinical and transferable aspects of leukaemia and other malignant blood diseases in order to find a cure for them.

# Vision

The Josep Carreras Leukaemia Research Institute's vision is to be a world-renowned, multi-campus research centre of excellence that contributes towards improved outcomes and a cure for leukaemia and other malignant blood diseases through innovation, sustainability, social responsibility, talent and professional expertise.

# Values

Altruism and example-setting, in accordance with the Foundation's principles.

Patient-orientated, proximity.

Staff commitment and correlation.

Mutual respect.

Corporate alignment of the 3 campuses and the Foundation.

Participative and shared leadership.

Continuing cooperation agreements and the forging of alliances.

The integration of research and health care.

Continuous improvement and perseverance as guiding principles.

Conceptual, methodological and technological innovation.

Sustainable management.

Procedural efficacy.

Efficiency in the optimisation of resources.

Transparency, public dissemination and openness.

Continuous evaluation and accountability.





Our team

# Governing Bodies

The highest governing body is the Board of Trustees, on which are represented: the Josep Carreras Foundation, the Catalan Government Ministry of Business and Knowledge, the Catalan Government Ministry of Health, the Autonomous University of Barcelona (UAB), the University of Barcelona (UB), Badalona Town Council, the Directorate General for Health Research and Planning, the Catalan Institute of Oncology, the Northern Metropolitan Territorial Area Administration, the Catalan Foundation for Research and Innovation, the Hospital Clínic/August Pi i Sunyer Institute for Biomedical Research (Idibaps), the UB Hospital Coordination Committee and the Research Centres of Catalonia Institution Foundation (iCERCA).

## Board of Trustees

### President

**Mr. Josep Carreras Coll** President of the Josep Carreras Foundation and the Josep Carreras Leukaemia Research Institute

### First Vice-president

**Mr. Jordi Baiget i Cantons** Catalan Government Minister of Business and Knowledge

### Second Vice-president

**Mr. Antoni Comín i Oliveras** Catalan Government Minister of Health

### Members

**Margarita Arboix Arzo**  
Rector Autonomous University of Barcelona (UAB)

**Joan Elias Garcia**  
Rector University of Barcelona (UB)

**Maria Dolors Sabater i Puig**  
Mayor of Badalona

---

**Francesc Subirada i Curcó** Director General for Research, Catalan Government Ministry of Business and Knowledge

**Antoni Andreu Pérez** Director General for Health Research and Planning

**Montserrat Llavayol i Giralt** Deputy Director General for Health Research and Planning

### **Candela Calle Rodríguez**

Director General Catalan Institute of Oncology

### **Jordi Ara del Rey**

Administrator Northern Metropolitan Territorial Area

**Arcadi Navarro Cuartiellas** Secretary for Universities and Research, Catalan Government Ministry of Business and Knowledge

**Rafael Marin Gálvez** Director Catalan Foundation for Research and Innovation

### **Eliás Campo Güerri**

Research Director Hospital Clínic - IDIBAPS

### **Albert Carreras Coll**

Treasurer of the Josep Carreras Leukaemia Foundation

**Ciril Rozman Borstnar** Former Vice-president of the Josep Carreras Leukaemia Foundation

### **Evarist Feliu Frasnado**

Vice-president of the Josep Carreras Leukaemia Foundation

### **Antoni Garcia Prat**

Administrator of the Josep Carreras Leukaemia Foundation

### **Armand Sanchez Bonastre**

Vice-rector for Research and Transferability, Autonomous University of Barcelona (UAB)

### **César Picado Vallés**

University of Barcelona Hospital Coordination Committee

### Secretary

#### **Lluís Rovira Pato**

Director of the Research Centres of Catalonia Institution Foundation (iCERCA)



## Delegate Committee

---

### President

**Prof. Evarist Feliu,**  
Coordinator of the ICO-Germans Trias i Pujol  
Campus

### Members

**Francesc Subirada i Curcó**  
Director General for Research, Catalan  
Government Ministry of Business and Knowledge

**Dr. Antoni Andreu Périz**  
Director general for health research and innovation

**David Elvira i Martínez**  
Director of the Catalan Health Service

**Jaume Raventós**  
Director of the Catalan Research Service

**Dr. Lluís Rovira Pato**  
Director iCerca, CERCA Institution, Research  
Centres of Catalonia

**Mr. Antoni García Prat**  
Administrator, Josep Carreras International  
Foundation

**Dr César Picado Vallés**  
University of Barcelona Hospital Coordination  
Committee Chairman

**Dr. Lluís Tort Bardolet**  
Vice-rector for Strategic Projects and Planning,  
Autonomous University of Barcelona

## External Scientific Committee

---

### President

Prof. Lucio Luzzatto, Nigerian Haematology  
Association

### Members

Prof. Robert Sackstein, Dana-Farber/Harvard Cancer  
Center Boston

Prof. Francesco Lococo, Università degli Studi di Roma  
"Tor Vergata"

Prof. Alberto Orfao, CIC Centro de Investigación del  
Cáncer Salamanca.

Prof. Brigitte Schlegelberger, University of Hannover

## Internal Scientific Committee

---

### UB-Clínic Campus

Álvaro Urbano Ispizúa (Internal Scientific  
Committee Coordinator)

Pablo Menéndez (Campus Research Director)

Jordi Esteve Reyner

Armando López Guillermo

Joan Bladé Creixentí

Francisco Cervantes Requena

### ICO-GTiP Campus

Evarist Feliu Frasnado (President of the Delegate  
Committee)

Francesc Solé (Campus Research Director)

Josep M<sup>a</sup> Ribera Santasusana

Lurdes Zamora Plana

José Tomás Navarro Ferrando

Juan Manuel Sancho Cía

### Sant Pau Campus

Jordi Sierra

Josep Nomdedeu


Joan Carles Souto

Ramon Mangues

Carol Moreno



# Organisational chart



## Scientific Directors



ICO-GTP Campus  
Francesc Solé



Clínic-UB Campus  
Pablo Menéndez



Sant Pau Campus  
Jordi Sierra

# Human resources

## IJC Germans Trias

---

### Linked with IJC

Aranda Cebrian, Jessica  
Barque Falguera, Anna  
Batista, Lopes  
Buschbeck, Marcus  
Cid Roldos, Emili  
Corujo Garcia, David  
Couso de la Torre, Jorge  
de Haro Camps, Núria  
Diesch, Jeannine  
Douet Julien, Thierry  
Estrada Barreras, Natalia  
Fita Torro, Josep  
Fuster Tormo, Francisco  
Garcia Calduch, Olga  
Garcia Rico, Laura  
Genesca Ferrer, Eulalia  
Gomes Monteiro, Maria Joao  
Gomez Marzo, Paula  
Guberovic, Iva  
Hurtado, Sarah  
Ibarra Fernandez, Gladys  
Llobet Reixach, Laura  
Maher, Michael  
Malinverni, Roberto  
Mallo Fajula, Maria del Mar  
Muncunill Farreny, Josep  
Palomo Sanchis, Laura  
Pasquali, Lorenzo  
Petriz Gonzalez, Jorge Mario  
Ribera Salas, Jordi  
Ruiz Cortes, Rocio  
Sanchez Fernandez, M  
Carmen  
Solanes Hernandez, Neus  
Sole Ristol, Francesc  
Valero Lazaro, Vanesa  
Vavouri, Sultana  
Vidal Santorum, Adria  
Yamamoto, Fumiichiro  
Yamamoto, Miyako

## IJC Clínic

---

### Linked with IJC

Agraz Doblás, Antonio Manuel  
Banus Mulet, Antonia  
Bueno Uroz, Clara  
Castaño Cardoso, Julio  
Cobo Sanchez, Isabel  
Diaz de la Guar Quiles, Rafael  
Dominguez Mohedano, Sonia  
Etxabe Alberdi, Amaia  
Fernandez Martin, Adrian  
Gutierrez Valle, Victoria  
Krishnevskaya, Elena  
Liberio Baroni, Matteo  
Llaudet Planas, Esther  
Lopez Millan, Belen  
Mañu Pereira, Maria del Mar  
Masso Chacon, Anna  
Menendez Bujan, Pablo  
Mir Fuertes, Enrique  
Molina Campoy, Oscar  
Muñoz Risueño, Ruth  
Palomo de Udaeta, Marta  
Prieto Fernandez, Cristina  
Rizzutto, Valeria  
Roca Ho, Heleia  
Rodriguez Cortez, Virginia  
Suñe Rodriguez, Guillermo  
Torres Ruiz, Raul

## IJC Sant Pau

---

### Linked with IJC

Aljarilla Medina, Alba  
Esquirol Sanfeliu, Albert  
Millon Caño, Juan Antonio  
Virgin Alamo Vargas, Patricia

## IJC Germans Trias ICO-UAB



### Linked with hospital

Batlle, Montse. Post doc  
Cabezón, Marta. Post doc  
Cisneros, Adela. Pre doc  
Feliu, Evarist. Director  
Ferra, Christelle. LR  
Granada, Isabel. Post doc  
Grau, Javier. Post doc  
Junca, Jordi. Post doc  
Marce, Silvia. Post doc  
Milla, Fuensanta. Post doc  
Navarro, Tomàs. LR  
Oriol, Albert. LR  
Ribera, Josep Maria. LR  
Rodríguez, Inés. Pre doc  
Ruiz, Neus. Pre doc  
Sancho, Juanma. LR  
Vives, Susana. Pre doc  
Xandri, Marisol. Pre doc  
Xicoy, Blanca. LR  
Zamora, Lurdes. LR

## IJC Clínic-UB



### Linked with hospital

Blade, Joan. LR  
Esteve, Jordi. LR  
Larrea, Carlos. Post doc  
Urbano, Alvaro. Director


## IJC Sant Pau



### Linked with hospital


Barata, Ana. Post doc  
Briones, Javier. LR  
Mangues, Ramon. LR  
Moreno, Carol. LR  
Nomdedeu, Josep. LR  
Pratcorona, Marta. Post doc  
Sierra, Jordi. Director

	IJC ICO Germans Trias UAB	IJC Clínic UB	IJC Sant Pau UAB	IJC Shared
Lead researchers	7	3		
Pre-doctoral researchers	14	9		
Post-doctoral researchers	7	7	1	
Support staff	10	8	3	
Management and administration staff	1			25
<b>Staff professionally linked with the IJC</b>	<b>39</b>	<b>27</b>	<b>4</b>	<b>25</b>
<b>Staff professionally linked with the Hospital</b>	<b>30</b>	<b>15</b>	<b>19</b>	





At the three hospitals where the IJC has a presence there has always been a great willingness to participate in clinical research. And there are clinics with a very considerable background in basic sciences. Integration, in this respect, must therefore not be just a question of maintaining present levels, but of increasing them in order to enhance the added value it represents in both the health sciences and in clinical practice.



# Financial data

# Income statement

In 2016 there was an increase of more than 7% in income from the capture of public funds and the provision of services.

With regard to expenses, 60% of the IJC's outlay corresponds to staffing, with an increase of 14%. At this early stage the evolution of income, expenses and investments gives a negative result of €472,531.22.




<b>Income from activities</b>	<b>€3,603,917.96</b>
Services rendered	€591,733.98
Official subsidies for activities	€2,356,251.98
Other subsidies. donations...	€655,932.00
<b>Self-constructed assets</b>	<b>€10,517.60</b>
<b>Supplies</b>	<b>- €860,955.55</b>
<b>Other income from activity</b>	<b>€20,404.62</b>
<b>Staff costs</b>	<b>- €2,149,326.75</b>
Wages and salaries	- €1,686,478.26
Social security expenses	- €462,848.49
<b>Other expenses</b>	<b>- €605,889.15</b>
External services	- €591,785.93
Taxes	- €474.83
Losses, depreciation...	- €10,517.60
Other current period losses	- €3,110.79
<b>Fixed asset depreciation</b>	<b>- €525,869.73</b>
<b>IJC Subsidy</b>	<b>€53,338.50</b>
<b>Other income</b>	<b>€1,938.20</b>
<b>OPERATING INCOME</b>	<b>- €451,924.30</b>
<b>Financial income</b>	<b>€208.24</b>
<b>Financial expenses</b>	<b>- €19,940.62</b>
<b>Subsidy return expenses</b>	<b>- €379.47</b>
<b>Exchange rate differences</b>	<b>- €874.54</b>
<b>Financial result</b>	<b>- €20,606.92</b>
<b>Surplus / deficit before tax</b>	<b>- €472,531.22</b>
Tax on profit	-
<b>SURPLUS / DEFICIT OF THE FINANCIAL YEAR</b>	<b>- €472,531.22</b>

# Balance sheet

<b>ASSETS</b>	
<b>Non-current assets</b>	<b>€13,671,488.67</b>
Intangible fixed assets	€2,062,459.46
Tangible fixed assets	€11,576,049.93
Long-term investments in group and associated entities	€2,000.00
Long-term financial investments	€30,979.28
<b>Current assets</b>	<b>€5,860,833.65</b>
Stock	€14,879.00
Users, sponsors and other debtors from activities	€5,716,590.75
Other credits with the public administration	
Short-term financial investments	-
Short-term accruals	€18,168.09
Cash and others	€111,195.81
<b>TOTAL ASSETS</b>	<b>€19,532,322.32</b>
<b>LIABILITIES</b>	
<b>Net assets</b>	<b>€11,478,998.01</b>
<b>Equity</b>	<b>€10,269,001.97</b>
Start-up funds	€11,660,719.37
Special funds	
Profit or loss from previous years	- €919,186.18
Year profit or loss	- €472,531.22
Subsidies, donations and legacies	€1,209,996.04
<b>Non-current liabilities</b>	<b>€3,616,843.21</b>
Long-term debt	€3,616,843.21
<b>Current liabilities</b>	<b>€4,436,481.10</b>
Short-term provisions	€10,517.60
Short-term debt	€2,359,223.16
Creditors for activities and others	€1,327,251.71
Short-term debts with group and associated entities	
Current tax liabilities and other debts with the public administration	
Short-term accruals	€739,488.63
<b>TOTAL (LIABILITIES + NA)</b>	<b>€19,532,322.32</b>


# Evolution of income





# Scientific activity

# Research groups



## IJC Germans Trias

Active projects

23

LRs

7

## IJC Clínic

Active projects

16

LRs

3

# Competitive funding granted


IP	Projects 2016	Amount
Marcus Buschbeck	BFU MINECO	€201.000,00
Marcus Buschbeck	ITN H2020	€549.202,86
Natalia Estrada	FI AGAUR	€45.000,00
Ruth Muñoz	RETOS COLABORACIÓN MINECO	€181.000,00
Ruth Muñoz	SAF MINECO	€201.586,00
Clara Bueno	AECC	€150.000,00
Jose M <sup>a</sup> Ribera	AECC	€487.000,00
Jose M <sup>a</sup> Ribera	IMI	€153.348,00
Tanya Vavouri	BFU MINECO	€142.000,00
Mayka Sanchez	Doctorado Industrial	€33.960,00
Mayka Sanchez	Ramón Areces	€120.000,00
Mayka Sanchez	RETOS MIENCO	€108.900,00
Pablo Menendez	RETOS COLABORACIÓN MINECO	€123.562,00
Raul Torres	LADY TATA	€40.000,00
Mar Mañu	H2020	€205.766,88
		<b>€2.742.325,74</b>





# Capturing competitive grants

	ICO Germans UAB	Clínic UB
Active projects (national)	19	13
Projects awarded (national)	7	4
Projects tendered (national)	28	17
Active projects (international)	3	3
Projects awarded (international)	3	1
Projects tendered (international)	5	4
Projects awarded (public)	10	5
Projects awarded (private)	18	
Active research networks	1	
Research networks awarded		
<b>Competitive funding granted (€)</b>	<b>€1.559.177,00</b>	<b>€1.183.148,00</b>
<b>Non-competitive funding granted (€)</b>	<b>€512.623,00</b>	<b>€173.000,00</b>
<b>Sum total competitive and non-competitive overheads granted</b>	<b>€285.379,00</b>	<b>€165.075,00</b>



# Technology platforms

## Cytogenetics platform



The Josep Carreras Leukaemia Research Institute cytogenetics platform is directed by Dr. Francesc Solé. The platform includes the Catalan Institute of Oncology's (ICO) Cytogenetics Laboratory and the 32K Bacterial Artificial Chromosome (BAK) library.

## Affymetrix Microarrays Platform



The Affymetrix® Microarrays Platform (AMP) is a service focused on microarray DNA and RNA solutions provided by Affymetrix. The main aim is to find solutions, based on basic research, applied research and diagnosis, that lead towards personalised medicine.

## Blood cancer samples



The administration of the collection, processing and storage of blood cancer samples. These samples are stored in a collection called 'Collection of samples from patients with hematologic neoplasms'.

## Fluidigm Platform




The Fluidigm platform is used to create integrated fluid circuits (IFCs) which are single-use biochips which automate PCR reactions using the volumes of nanolitres from two samples and reagents to produce consistent results.

## Clinical trials

Clinical trials are a fundamental part of our research. In this regard, the IJC evaluates treatments, the efficacy of drugs, and the suitability of equipment.

It enables new treatments to be tested to prevent, relieve or cure diseases.



## Transferability and innovation

The IJC vouches for the transferability of knowledge, and the value of and search for market opportunities, in the broadest terms. As well as being in its own interests, it contributes to society and our country's progress.

At the present time the IJC has the following patent pending:

Methods for treating, diagnosing and prognosing a haematological malignancy.

Inventor: Ruth Muñoz Risueño

WO 2015/197839

PCT/EP2015/064571

**(81) Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

**(84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**


— with international search report (Art. 21(3))




# Scientific production

# Publications

## Indexed articles



## Global impact factor



## Publications 2016

Total articles  
**99**

Total FI articles  
**99**


Accumulated impact factor  
**797.498**

FI 1Q  
**543.993**

Total citations  
**1,221**

Citation index  
**39.976**

Articles 1st quartile



A woman is shown in profile, sitting on a stone ledge. She is wearing a white, textured knit sweater and a colorful headscarf with geometric patterns in teal, orange, and red. Her hands are clasped together on the ledge. She is looking out over a residential street with trees and buildings in the background. The scene is brightly lit, suggesting a sunny day.

# Teaching activities

# Teaching

The IJC provides a high-quality teaching programme for students, scientists, technicians and others with an interest in achieving a solid and up-to-date grounding in the field of leukaemia and malignant blood diseases.

The IJC organises a Doctorate in Hematology, a Master's degree in malignant blood diseases and it participates in the teaching for degrees in medicine and biomedicine.

Staff linked to the University

7

Theses read

3

Doctorates being prepared

6

In 2016 the following theses were presented at the IJC:

**Splenic marginal zone lymphoma cytogenetics**

Doctoral student: Cristina Baró (UAB)  
Director: Francesc Solé  
Barcelona, 1 February 2016

**The Iron Regulatory Protein/Iron Responsive Element (IRP/IRE) system: functional studies of new target mRNAs and pathological implications for novel IRE mutations**

Doctoral student: Sara Luscieti UB  
Director: Dr. Mayka Sanchez  
22 November 2016

**Polycomb repressive complex 1 functions in differentiation and myelodysplastic syndromes.**

Doctoral student: Anna Palau de Miguel UB  
Director: Marcus Buschbech  
30 November 2016



# Training

The IJC organises complementary training activities at all levels, from scientific conferences, monthly seminars and technology sessions, to specialised courses.

Training courses

5

Scientific conference

1

Scientific seminars

24



# Internal sessions

## **MDS GRUP**

**Francesc Solé**

Francisco Fuster

## **MPN GROUP**

**Lurdes Zamora, Blanca Xicoy**

Natalia Estrada, Laura Palomo

## **GLICOLSILATION GROUP**

**Fumi Yamamoto**

Emili Cid

## **ALL GROUP**

**JM Ribera**

Eulalia Genescà, Jordi Ribera

## **MYELOMA GROUP**

**Albert Oriol**

Paula Gomez

## **CLL GROUP**

**M<sup>a</sup> Joao Batista, Christelle Ferra**

Maria Joao Baptista

## **FUNCTIONAL CYTOMICS**

**Jordi Petriz**

Laura Garcia

## **IRON GROUP**

**Mayka Sanchez**

Jorge Couso, Ana Barque

## **CHROMATIN GROUP**

**Marcus Buschbeck**

Anna Palau, Sara Alvarez, Jeannine

Diesch



# Seminars

**8 March 2016 at 15.30**

**Exploring approaches for molecular risk stratification in MDS**

Dr. Rafael Bejar. University of California, San Diego (Department of Medicine)  
MDS Group Dr. Francesc Solé

**21 March 2016 at 15.30**

**Our experience of a CART19 approach in Barcelona "or" CARs for anti-tumor immunotherapy**

Dr. Manel Juan. Hospital Clínic Biomedical Diagnostic Centre (Immunology)  
Immunohematology and glicobiology Dr. Fumi Yamamoto

**25 April 2016 at 15.30**

**Novel antigens expressed in Leukemic Stem Cells**

Dr. Lidia Campos. Centre Hospitalier Universitaire de Saint Etienne. Head Laboratory Hematologist.  
Functional Cytomics Dr. Jordi Pétriz

**2 May 2016 at 15.30**

**Clinical implications of CLL genetics**

Dr. Davide Rossi. Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont.  
CLL Group Drs. Maria Joao Baptista, Christelle Ferrà and Inés Rodríguez

**9 May 2016 at 15.30**

**Pathophysiological consequences of the disruption of the Hpcidin-Ferroportin regulatory circuitry**

Dr. Sandro Altamura. Developmental Biology, Genetics, Molecular Biology MS, PhD. Universität Heidelberg, Heidelberg  
Iron metabolism: regulation and diseases  
Dr. Mayka Sánchez

**23 May 2016 at 15.30**

**Immunotherapy of lymphoid malignancies with dendritic cells and NKT cell agonists**

Dr. Javier Briones. Hospital Sant Pau. Hematology Service  
Immunohematology and glicobiology Dr. Fumi Yamamoto

**29 May 2016 at 15.30**

**Genomics in multiple myeloma**

Dr. Norma Gutierrez, associate doctor in hematology, Hospital de Salamanca and lead researcher at the Institute for Biomedical Research of Salamanca (IBSAL)  
Myeloma Group Dr. Albert Oriol

**6 June 2016 at 15.30**

**Clinical and biological aspects of splenic marginal zone lymphoma**

Dr. Estela Matutes. Hematopathology Unit Hospital Clínic, Barcelona.  
Myeloma Group Dr. Albert Oriol

**20 June 2016 at 15.30**

**MSC in myeloid malignancies**

Dr. Thomas Schroeder. Medical Director of Radiation Oncology in UNM (Comprehensive Cancer Center)  
Genetics and Epigenetics of Myeloid Neoplasms  
Dr. Lourdes Zamora

**26 September 2016 at 15.30**

**MRD assessment in ALL: from PCR/flow to next generation sequencing**

Dr. Monika Brüggemann. Department of Hematology. University Hospital Schleswig-Holstein  
ALL Group Dr. Josep M<sup>a</sup> Ribera

**12 December 2016 at 15.30**

**The broad molecular and clinical spectrum of follicular lymphomas**

Andreas Rosenwald. Professor of Pathology, Chairman. Institute of Pathology. University of Wuerzburg.  
Lymphoid Neoplasms Dr. Tomás Navarro



# Courses

## Cytogenetics and Molecular Genetics Applied for the study of Hematological Neoplasms



**Dates:**

15-16 March, 2016  
17-18 May, 2016  
31 May-1 June, 2016

**Venue:**

Institut de Recerca Contra la Leucèmia Josep Carreras  
Ctra. de Can Ruti, Camí de les Escoles s/n  
IMPPC building  
08916 Badalona (Barcelona)



## Fluorescence in situ hybridization (FISH) applied to the diagnosis of myelodysplastic syndromes and other hematological neoplasms



**Dates:**

18-19 June  
29-30 October  
19-20 November

**Venue:**

Institut de Recerca Contra la Leucèmia Josep Carreras  
Ctra. de Can Ruti, Camí de les Escoles s/n  
IMPPC building  
08916 Badalona (Barcelona)



### **Cytogenetics and Molecular Genetics of Myeloid Neoplasms.**

Celgene Internacional. Badalona, 15-16 March 2016.

Director: Francesc Solé. In collaboration with: Mar Mallo, Vera Ademà, Laura Palomo. Blanca Espinet, Marta Salido.

### **Cytogenetics and Molecular Genetics of Myeloid Neoplasms.**

Celgene Internacional. Badalona, 17-18 May 2016.

Director: Francesc Solé. In collaboration with: Mar Mallo, Vera Ademà, Laura Palomo. Blanca Espinet, Marta Salido.

### **Cytogenetics and Molecular Genetics of Myeloid Neoplasms.**

Celgene Internacional. Badalona, 31 May - 1 June 2016.

Director: Francesc Solé. In collaboration with: Mar Mallo, Vera Ademà, Laura Palomo. Blanca Espinet, Marta Salido.

### **Latest advances in acute lymphoblastic leukaemia.**

Badalona, 8 and 9 September 2016.


Director: Josep Maria Ribera

### **Cytogenetics applied to the study of blood diseases. Expert in bases of hematology diagnosis.**

IL3-UB. Madrid, 9 November 2016.

Speakers: Francesc Solé/Mar Mallo

# Communication and congresses





# Cooperation

# Agreements

The IJC makes a great effort to establish continuing cooperation agreements, and it aims to broaden its strategic alliances and agreements with the pharmaceutical industry, as well as other private organisations. At the present time the following institutions are connected with the IJC:





# Communication

# Communication

The IJC knows that it is of prime importance to tell people about the work we do if we are to strengthen our bonds with society and its citizens. The desire to integrate social corporate responsibility into our management model is closely linked to the organisational values of the Josep Carreras Foundation.

To this end, the IJC has actively participated in scientific dissemination and in the creation of scientific vocations.

## Rotary Club of Badalona



## Children's council visit Tiana town council



## Science week, Badalona town council





# Upcoming challenges



# Upcoming challenges

## Inauguration of the new building



In the autumn of 2017 the IJC will take a big step forward in the field of research into leukaemia with the inauguration of the new building in Badalona.

The new building has 10,000m<sup>2</sup> of floor space, and it is the first European research centre to be exclusively focused on research into leukaemia and other malignant blood diseases.

Furthermore, it has been accredited as a sustainable building on account of its reduced environmental impact, savings in energy consumption, reduction in maintenance costs and the increased satisfaction and wellbeing of the people who use it.

## Strategic Plan 2018 – 2022



The Josep Carreras Leukaemia Research Institute has to have a very clear idea of its strategic horizon, and it has to have an organisational culture that is shared by everyone involved.

In 2017 the IJC starts out on a new phase and it will draw up the bases for a constructive and participative Strategic Plan that will be the road map setting out the answers to future challenges. The IJC has new challenges ahead and all the enthusiasm with which to face them together.

We are improving now to build tomorrow!



# Annex



## Scientific production 2016

- 1 Akerman I, Tu Z, Beucher A, Rolando DM, Sauty-Colace C, Benazra M, Nakic N, Yang J, Wang H, Pasquali L, Moran I, Garcia-Hurtado J, Castro N, Gonzalez-Franco R, Stewart AF, Bonner C, Piemonti L, Berney T, Groop L, Kerr-Conte J, Pattou F, Argmann C, Schadt E, Ravassard P, Ferrer J.  
Human Pancreatic  $\beta$  Cell lncRNAs Control Cell-Specific Regulatory Networks.  
CELL METAB 2016 Dec 28. pii: S1550-4131(16)30595-2. doi: 10.1016/j.cmet.2016.11.016. [Epub ahead of print] Article  
Impact Factor: 17,303
- 2 Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P.  
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.  
BLOOD 2016 Sep 1;128(9):1174-80. doi: 10.1182/blood-2016-03-707596.  
Article  
Impact Factor: 11,841
- 3 Barata A, Wood WA, Choi SW, Jim HS.  
Unmet Needs for Psychosocial Care in Hematologic Malignancies and Hematopoietic Cell Transplant. CURR HEMATOL MALIG R 2016 Aug;11(4):280-7. doi: 10.1007/s11899-016-0328-z. Review.  
Article  
Impact Factor: 2,146
- 4 Barta SK, Joshi J, Mounier N, Xue X, Wang D, Ribera JM, Navarro JT, Hoffmann C, Dunleavy K, Little RF, Wilson WH, Spina M, Galicier L, Noy A, Sparano JA.  
Central nervous system involvement in AIDS-related lymphomas.  
BRIT J HAEMATOL 2016 Jun;173(6):857-66. doi: 10.1111/bjh.13998. Epub 2016 Apr 7.  
Article  
Impact Factor: 5,401
- 5 Blanco G, Puiggros A, Baliakas P, Athanasiadou A, García-Malo M, Collado R, Xochelli A, Rodríguez-Rivera M, Ortega M, Calasanz MJ, Luño E, Vargas M, Grau J, Martínez-Laperche C, Valiente A, Cervera J, Anagnostopoulos A, Gimeno E, Abella E, Stalika E, Hernández-Rivas JM, Ortuño FJ, Robles D, Ferrer A, Ivars D, González M, Bosch F, Abrisqueta P, Stamatopoulos K, Espinet B.  
Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.  
ONCOTARGET 2016 Dec 6;7(49):80916-80924. doi: 10.18632/oncotarget.13106.  
Article  
Impact Factor: 5,008
- 6 Borghesan M, Fusilli C, Rappa F, Panebianco C, Rizzo G, Oben JA, Mazzoccoli G, Faulkes C, Pata I, Agodi A, Rezaee F, Minogue S, Warren A, Peterson A, Sedivy JM, Douet J, Buschbeck M, Cappello F, Mazza T, Paziienza V, Vinciguerra M. DNA Hypomethylation and Histone Variant macroH2A1 Synergistically Attenuate Chemotherapy-Induced Senescence to Promote Hepatocellular Carcinoma Progression.  
CANCER RES 2016 Feb 1;76(3):594-606. doi: 10.1158/0008-5472.CAN-15-1336. Epub 2016 Jan 15.  
Article  
Impact Factor: 8,556



- 7 Botin T, Navarro JT, Juncà J, Mate JL. [Leukemic transformation cell sarcoma]. MED CLIN-BARCELONA 2016 May 6;146(9):418-9. doi: 10.1016/j.medcli.2015.11.039. Epub 2016 Jan 26.  
Carta  
Impact Factor: 1,267
- 8 Bueno C, van Roon EH, Muñoz-López A, Sanjuan-Pla A, Juan M, Navarro A, Stam RW, Menendez P. Immunophenotypic analysis and quantification of B-1 and B-2 B cells during human fetal hematopoietic development. LEUKEMIA 2016 Jul;30(7):1603-6. doi: 10.1038/leu.2015.362. No abstract available.  
Article  
Impact Factor: 12,104
- 9 Cantarino N, Musulen E, Valero V, Peinado MA, Perucho M, Moreno V, Forcales SV, Douet J, Buschbeck M. Downregulation of the Deiminase PADI2 is an Early Event in Colorectal Carcinogenesis and Indicates Poor Prognosis. MOL CANCER RES 2016 Sep;14(9):841-8. doi: 10.1158/1541-7786.MCR-16-0034. Epub 2016 Jun 8.  
Article  
Impact Factor: 4,510
- 10 Cantariño N, Fernández-Figueras MT, Valero V, Musulén E, Malinverni R, Granada I, Goldie SJ, Martín-Caballero J, Douet J, Forcales SV, Buschbeck M. A cellular model reflecting the phenotypic heterogeneity of mutant HRAS driven squamous cell carcinoma. INT J CANCER 2016 Sep 1;139(5):1106-16. doi: 10.1002/ijc.30139. Epub 2016 May 5.  
Article  
Impact Factor: 5,531
- 11 Castaño J, Herrero AB, Bursen A, González F, Marschalek R, Gutiérrez NC, Menendez P. Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair. ONCOTARGET 2016 May 24;7(21):30440-52. doi: 10.18632/oncotarget.8938.  
Article  
Impact Factor: 5,008
- 12 Céspedes MV, Fernández Y, Unzueta U, Mendoza R, Seras-Franzoso J, Sánchez-Chardi A, Álamo P, Toledo-Rubio V, Ferrer-Miralles N, Vázquez E, Schwartz S, Abasolo I, Corchero JL, Mangués R, Villaverde A. Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. SCI REP-UK 2016 Oct 24;6:35765. doi: 10.1038/srep35765.  
Article  
Impact Factor: 5,228
- 13 Céspedes MV, Guillén MJ, López-Casas PP, Sarno F, Gallardo A, Álamo P, Cuevas C, Hidalgo M, Galmarini CM, Allavena P, Avilés P, Mangués R. Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models. DIS MODEL MECH 2016 Dec 1;9(12):1461-1471.  
Article  
Impact Factor: 4,316
- 14 Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I, Pavón MA, Mangués MA, Trías M, López-Pousa A, Villaverde A, Vázquez E, Mangués R. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4(+) colorectal cancer models. NANOMEDICINE-UK 2016 Oct;12(7):1987-1996. doi: 10.1016/j.nano.2016.04.003.  
Article  
Impact Factor: 4,889



- 15 Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, et al.  
GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. *BONE MARROW TRANSPL* 2016 Dec 12. doi: 10.1038/bmt.2016.265. [Epub ahead of print] Article  
Impact Factor: 3,636
- 16 Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R.  
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.  
*LEUKEMIA* 2016 Dec 27. doi: 10.1038/leu.2016.390. [Epub ahead of print] Article  
Impact Factor: 12,104
- 17 Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, Iacobelli M, Niederwieser D, Olavarria E, Suarez F, Ruutu T, Verdonck L, Hume R, Nejadnik B, Lai C, Finetto G, Richardson P.  
Defibrotide for the Treatment of Hepatic Venous Occlusive Disease: Final Results From the International Compassionate- Use Program.  
*BIOL BLOOD MARROW TR* 2016 Oct;22(10):1874-82. doi: 10.1016/j.bbmt.2016.07.001.  
Article  
Impact Factor: 3,980
- 18 Cornet-Masana JM, Moreno-Martínez D, Lara-Castillo MC, Nomdedeu M, Etxabe A, Tesi N, Pratcorona M, Esteve J, Risueño RM.  
Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells. *ONCOTARGET* 2016 Apr 26;7(17):23239-50. doi: 10.18632/oncotarget.8096.  
Article  
Impact Factor: 5,008
- 19 Corujo D, Mas G, Malinverni R, Di Croce L, Buschbeck M.  
Barcelona conference on epigenetics and cancer 2015: Coding and non-coding functions of the genome. *EPIGENETICS-US* 2016 Jan 2;11(1):95-100. doi: 10.1080/15592294.2015.1131377.  
Article  
Impact Factor: 4,774
- 20 Dalgaard K, Landgraf K, Heyne S, Lempradl A, Longinotto J, Gossens K, Ruf M, Orthofer M, Strogantsev R, Selvaraj M, Lu TT, Casas E, Teperino R, Surani MA, Zvetkova I, Rimmington D, Tung YC, Lam B, Larder R, Yeo GS, O'Rahilly S, Vavouri T, Whitelaw E, Penninger JM, Jenuwein T, Cheung CL, Ferguson-Smith AC, Coll AP, Körner A, Pospisilik JA.  
Trim28 Haploinsufficiency Triggers Bi-stable Epigenetic Obesity. *CELL* 2016 Jan 28;164(3):353-64. doi: 10.1016/j.cell.2015.12.025.  
Article  
Impact Factor: 28,710
- 21 Diesch J, Zwick A, Garz AK, Palau A, Buschbeck M, Götze KS.  
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. *CLIN EPIGENETICS* 2016 Jun 21;8:71. doi: 10.1186/s13148-016-0237-y. eCollection 2016. Review.  
Revisio  
Impact Factor: 4,327



- 22 Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *LANCET ONCOL* 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.  
Article  
Impact Factor: 26,509
- 23 Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators.. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. *NEW ENGL J MED* 2016 Oct 6;375(14):1319-1331.  
Article  
Impact Factor: 59,558
- 24 Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafo AM, Raymakers R, San Miguel J, de Arriba F, Knop S, Röllig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki M, Moreau P. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUSTM (MM-010): a phase 3b study in refractory multiple myeloma. *BLOOD* 2016 Jul 28;128(4):497-503. doi: 10.1182/blood-2016-02-700872. Epub 2016 May 25.  
Article  
Impact Factor: 11,841
- 25 Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastiris E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iINNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia.. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iINNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. *LANCET ONCOL* 2016 Dec 9. pii: S1470-2045(16)30632-5. doi: 10.1016/S1470-2045(16)30632-5.  
Article  
Impact Factor: 26,509
- 26 Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenau P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *BLOOD* 2016 Nov 28. pii: blood-2016-08-733196. [Epub ahead of print]  
Article  
Impact Factor: 11,841
- 27 Fernandez Sojo J, Batlle Massana M, Morgades M, Vives Polo S, Quesada MD, Ribera Santasusana JM. [Comparative study on the usefulness of antibacterial prophylaxis with levofloxacin in patients submitted to hematopoietic stem cell transplantation]. *MED CLIN-BARCELONA* 2016 Jan 1;146(1):16-9. doi: 10.1016/j.medcli.2015.05.019. Epub 2015 Sep 3.  
Article  
Impact Factor: 1,267



- 28 Fernández-Álvarez R, Sancho JM, Ribera JM. [Plasmablastic lymphoma]. MED CLIN-BARCELONA 2016 Nov 4;147(9):399-404. doi: 10.1016/j.medcli.2016.06.036. Epub 2016 Aug 28. Article  
Impact Factor: 1,267
- 29 Forero-Castro M, Robledo C, Benito R, Abáigar M, África Martín A, Arefi M, Fuster JL, de Las Heras N, Rodríguez JN, Quintero J, Riesco S, Hermosín L, de la Fuente I, Recio I, Ribera J, Labrador J, Alonso JM, Olivier C, Sierra M, Megido M, Corchete-Sánchez LA, Ciudad Pizarro J, García JL, Ribera JM, Hernández-Rivas JM.  
Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome.  
PLOS ONE 2016 Feb 12;11(2):e0148972. doi: 10.1371/journal.pone.0148972. eCollection 2016. Article  
Impact Factor: 3,057
- 30 Forero-Castro M, Robledo C, Lumbreras E, Benito R, Hernández-Sánchez JM, Hernández-Sánchez M, García JL, Corchete-Sánchez LA, Tormo M, Barba P, Menárguez J, Ribera JM, Grande C, Escoda L, Olivier C, Carrillo E, García de Coca A, Ribera JM, Hernández-Rivas JM.  
The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.  
BRIT J HAEMATOL 2016 Feb;172(3):428-38. doi: 10.1111/bjh.13849. Epub 2015 Nov 16. Article  
Impact Factor: 5,401
- 31 García-Sanz R, Corchete LA, Alcoceba M, Chillon MC, Jiménez C, Prieto I, García-Álvarez M, Puig N, Rapado I, Barrio S, Oriol A, Blanchard MJ, de la Rubia J, Martínez R, Lahuerta JJ, González Díaz M, Mateos MV, San Miguel JF, Martínez-López J, Sarasquete ME; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.  
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.  
HEMATOL ONCOL 2016 Sep 8. doi: 10.1002/hon.2337. [Epub ahead of print] Article  
Impact Factor: 3,494
- 32 Gel B, Díez-Villanueva A, Serra E, Buschbeck M, Peinado MA, Malinverni R.  
regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests. BIOINFORMATICS 2016 Jan 15;32(2):289-91. doi: 10.1093/bioinformatics/btv562. Epub 2015 Sep 30. Article  
Impact Factor: 5,766
- 33 Gökbüget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, Chia V, Doubek M, Giebel S, Hoelzer D, Ifrah N, Katz A, Kelsh M, Martinelli G, Morgades M, O'Brien S, Rowe JM, Stieglmaier J, Wadleigh M, Kantarjian H. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.  
HAEMATOLOGICA 2016 Dec;101(12):1524-1533. Epub 2016 Sep 1. Article  
Impact Factor: 6,671
- 34 Gökbüget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, Doubek M, Fielding AK, Giebel S, Haddad V, Hoelzer D, Holland C, Ifrah N, Katz A, Maniar T, Martinelli G, Morgades M, O'Brien S, Ribera JM, Rowe JM, Stein A, Topp M, Wadleigh M, Kantarjian H.  
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.  
BLOOD CANCER J 2016 Sep 23;6(9):e473. doi: 10.1038/bcj.2016.84. Article  
Impact Factor: 4,411



- 35 González-Barca E, Canales MA, Salar A, Ferrer S, Domingo-Domenech E, Vidal MJ, Grande C, Bargay J, Gardella S, Oriol A, Briones J, García-Frade J, Bello JL, Sánchez-Blanco JJ, Peñalver FJ, Tomás JF, Asensio A, López A, Caballero D; GELTAMO Group (Grupo Español de Linfoma y Trasplante de Médula Ósea). Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. *ACTA HAEMATOL-BASEL* 2016;136(2):76-84. doi: 10.1159/000444625. Epub 2016 May 18.  
Article  
Impact Factor: 1,053
- 36 Gonzalo-Gil E, Pérez-Lorenzo MJ, Galindo M, Díaz de la Guardia R, López-Millán B, Bueno C, Menéndez P, Pablos JL, Criado G. Human embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase. *ARTHRITIS RES THER* 2016 Apr 1;18:77. doi: 10.1186/s13075-016-0979-0.  
Article  
Impact Factor: 3,979
- 37 Hartmann S, Schuhmacher B, Rausch T, Fuller L, Döring C, Weniger M, Lollies A, Weiser C, Thurner L, Rengstl B, Brunnberg U, Vornanen M, Pfreundschuh M, Benes V, Küppers R, Newrzela S, Hansmann ML. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. *LEUKEMIA* 2016 Apr;30(4):844-53. doi: 10.1038/leu.2015.328.  
Article  
Impact Factor: 12,104
- 38 Hernández AF, Menéndez P. Linking Pesticide Exposure with Pediatric Leukemia: Potential Underlying Mechanisms. *INT J MOL SCI* 2016 Mar 29;17(4):461. doi: 10.3390/ijms17040461. Review.  
Article  
Impact Factor: 3,257
- 39 Hernández-Boluda JC, Correa JG, García-Delgado R, Martínez-López J, Alvarez-Larrán A, Fox ML, García-Gutiérrez V, Pérez-Encinas M, Ferrer-Marín F, Mata-Vázquez MI, Raya JM, Estrada N, García S, Kerguelen A, Durán MA, Albors M, Cervantes F. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. *EUR J HAEMATOL* 2016 Dec 23. doi: 10.1111/ejh.12846. [Epub ahead of print]  
Article  
Impact Factor: 2,544
- 40 Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C; ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *ANN ONCOL* 2016 Sep;27(suppl 5):v69-v82. Epub 2016 Apr 7.  
Article  
Impact Factor: 9,269
- 41 Izura Gómez M, Batlle Massana M, Misis Del Campo M. [Response to high-dose cyclophosphamide in a patient with autoimmune hemolytic anemia refractory to conventional treatment]. *MED CLIN-BARCELONA* 2016 Sep 16;147(6):e33-4. doi: 10.1016/j.medcli.2016.05.006. Epub 2016 Jun 23.  
Carta  
Impact Factor: 1,267





42 Juncà J, Garcia O, Garcia-Caro M, Vila J, Zamora L, Cabezón M, Alonso E, de la Banda E, Rodríguez-Hernández I, Ribera JM, Millá F.

CD34 expression and the outcome of nucleophosmin 1-mutated acute myeloid leukemia. ANN HEMATOL 2016 Dec;95(12):1949-1954. Epub 2016 Sep 5.

Article

Impact Factor: 3,022

43 Kekre N, Marquez-Malaver FJ, Cabrero M, Piñana J, Esquirol A, Soiffer RJ, Caballero D, Terol MJ, Martino R, Antin JH, Lopez-Corral L, Solano C, Armand P, Pérez-Simon JA.

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.

BIOL BLOOD MARROW TR 2016 Oct;22(10):1808-15. doi: 10.1016/j.bbmt.2016.07.006.

Article

Impact Factor: 3,980

44 Kelleher N, Gallardo D, González-Campos J, Hernández-Rivas JM, Montesinos P, Sarrá J, Gil C, Barba P, Guàrdia R, Brunet S, Bernal T, Martínez MP, Abella E, Bermúdez A, Sánchez-Delgado M, Antònia C, Gayoso J, Calbacho M, Ribera JM; Pethema Group, Spanish Society of Hematology.

Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy.

LEUKEMIA LYMPHOMA 2016 Jan;57(1):86-91. doi: 10.3109/10428194.2015.1040013. Epub 2015 May 12.

Article

Impact Factor: 3,093

45 Lara-Castillo MC, Cornet-Masana JM, Etxabe A, Banús-Mulet A, Torrente MÁ, Nomdedeu M, Díaz-Beyá M, Esteve J, Risueño RM.

Repositioning of bromocriptine for treatment of acute myeloid leukemia. J TRANSL MED 2016 Sep 7;14:261. doi: 10.1186/s12967-016-1007-5.

Article

Impact Factor: 3,694

46 Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

LANCET 2016 Apr 9;387(10027):1551-60. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.

Article

Impact Factor: 44,002

47 Macia A, Widmann TJ, Heras SR, Ayllon V, Sanchez L, Benkaddour-Boumzaouad M, Munoz-Lopez M, Rubio A, Amador-Cubero S, Blanco-Jimenez E, Garcia-Castro J, Menendez P, Ng P, Muotri AR, Goodier JL, Garcia-Perez JL.

Engineered LINE-1 retrotransposition in non-dividing human neurons. GENOME RES 2016 Dec 13. pii: gr.206805.116. [Epub ahead of print] Article

Impact Factor: 11,351

48 Manils J, Eduard C, Viña-Vilaseca A, López-Cano M, Díez-Villanueva A, Gómez D, Marruecos L, Ferran M, Benito C, Perrino FW, Vavouri T, Maria de Anta J, Ciruela F, Soler C

The exonuclease TREX2 shapes psoriatic phenotype.

J INVEST DERMATOL 2016 Dec;136(12):2345-2355. doi: 10.1016/j.jid.2016.05.122. Epub 2016 Jun 27.

Article Impact Factor: 6,915



49 Martínez C, Millán O, Rovira M, Fernández-Avilés F, López A, Suárez-Lledó M, Carreras E, Urbano-Ispizua Á, Brunet M. Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation.  
INT J HEMATOL 2016 Nov 23. [Epub ahead of print] Article  
Impact Factor: 1,846

50 Martínez-Cibrian N, Magnano L, Gutiérrez-García G, Andrade X, Correa JG, Suárez-Lledó M, Martínez C, Rovira M, Carreras E, Rosiñol L, de Larrea CF, Cibeira MT, Gaya A, Gallego C, Hernando A, Creus N, Bladé J, Urbano-Ispizua Á, Fernández-Avilés F.  
At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study.  
BONE MARROW TRANSPL 2016 Apr;51(4):593-5. doi: 10.1038/bmt.2015.287. No abstract available. Article  
Impact Factor: 3,636

51 Matas-Céspedes A, Vidal-Crespo A, Rodríguez V, Villamor N, Delgado J, Giné E, Roca-Ho H, Menéndez P, Campo E, López-Guillermo A, Colomer D, Roué G, Wiestner A, Parren PW, Doshi P, van Bueren JL, Pérez-Galán P.  
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.  
CLIN CANCER RES 2016 Sep 16. doi: 10.1158/1078-0432.CCR-15-2095. [Epub ahead of print]  
Article  
Impact Factor: 8,738

52 Mateos MV, Granell M, Oriol A, Martínez-Lopez J, Blade J, Hernandez MT, Martín J, Gironella M, Lynch M, Bleickardt E, Paliwal P, Singhal A, San-Miguel J.  
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.  
BRIT J HAEMATOL 2016 Nov;175(3):448-456. doi: 10.1111/bjh.14263. Epub 2016 Jul 19.  
Article  
Impact Factor: 5,401

53 Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Arguiñano JM, Quintana N, García JL, Bladé J, Lahuerta JJ, Miguel JF.  
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.  
LANCET ONCOL 2016 Aug;17(8):1127-36. doi: 10.1016/S1470-2045(16)30124-3. Epub 2016 Jul 9.  
Article  
Impact Factor: 26,509

54 Mateos MV, Martínez-Lopez J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Martín Ramos ML, Oriol A, Bargay J, Bengoechea E, González Y, Pérez de Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Paiva B, Cedena MT, Puig N, Bladé J, Lahuerta JJ, San-Miguel J.  
Sequential versus alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.  
BLOOD 2016 Jan 28;127(4):420-5. doi: 10.1182/blood-2015-08-666537. Epub 2015 Oct 23.  
Article  
Impact Factor: 11,841



55 Mateos MV, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Palomera L, de Arriba F, Esseltine DL, Cakana A, Pei L, van de Velde H, Miguel JS.

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.

ANN HEMATOL 2016 Dec;95(12):2033-2041. Epub 2016 Oct 14.

Article

Impact Factor: 3,022

56 Muñoz-López A, Romero-Moya D, Prieto C, Ramos-Mejía V, Agraz-Doblas A, Varela I, Buschbeck M, Palau A, Carvajal-Vergara X, Giorgetti A, Ford A, Lako M, Granada I, Ruiz-Xivillé N, Rodríguez-Perales S, Torres-Ruiz R, Stam RW, Fuster JL, Fraga MF, Nakanishi M, Cazzaniga G, Bardini M, Cobo I, Bayon GF, Fernandez AF, Bueno C, Menendez P. Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency. STEM CELL REP 2016 Oct 11;7(4):602-618. doi:

10.1016/j.stemcr.2016.08.013.

Article

Impact Factor: 7,023

57 Muñoz-López Á, van Roon EH, Romero-Moya D, López-Millan B, Stam RW, Colomer D, Nakanishi M, Bueno C, Menendez P.

Cellular Ontogeny and Hierarchy Influence the Reprogramming Efficiency of Human B Cells into Induced Pluripotent Stem Cells.

STEM CELLS 2016 Mar;34(3):581-7. doi: 10.1002/stem.2303.

Article

Impact Factor: 5,902

58 Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, Maciejewski JP.

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. LEUKEMIA 2016 Dec;30(12):2405-2409. doi: 10.1038/leu.2016.228. No abstract available.

Article

Impact Factor: 12,104

59 Nicolle D, Fabre M, Simon-Coma M, Gorse A, Kappler R, Nonell L, Mallo M, Haidar H, Déas O, Mussini C, Guettier C, Redon MJ, Brugières L, Ghigna MR, Fadel E, Galmiche-Rolland L, Chardot C, Judde JG, Armengol C, Branchereau S, Cairo S.

Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management.

HEPATOLOGY 2016 Oct;64(4):1121-35. doi: 10.1002/hep.28621.

Article

Impact Factor: 11,711

60 Nomdedéu JF, Puigdecanet E, Bussaglia E, Hernández JJ, Carricondo M, Estivill C, Martí-Tutusa JM, Tormo M, Zamora L, Serrano E, Perea G, de Llano MP, García A, Sánchez-Ortega I, Ribera JM, Nonell L, Aventin A, Solé F, Brunet MS, Sierra J.

Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach.

HEMATOL ONCOL 2016 May 3. doi: 10.1002/hon.2304. [Epub ahead of print] Article

Impact Factor: 3,494



61 Nomdedeu M, Calvo X, Pereira A, Carrió A, Solé F, Luño E, Cervera J, Vallespí T, Muñoz C, Gómez C, Arias A, Such E, Sanz G, Grau J, Insunza A, Calasanz MJ, Ardanaz MT, Hernández-Rivas JM, Azaceta G, Álvarez S, Sánchez J, Martín ML, Bargay J, Gómez V, Cervero CJ, Allegue MJ, Collado R, Campo E, Esteve J, Nomdedeu B, Costa D; Spanish Group of Myelodysplastic Syndromes.

Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.

GENE CHROMOSOME CANC 2016 Apr;55(4):322-7. doi: 10.1002/gcc.22333. Epub 2015 Dec 22.

Article

Impact Factor: 3,960

62 Nunez-Espinosa C, Garcia-Godoy MD, Ferreira I, Rios-Kristjansson JG, Rizo-Roca D, Rico LG, Rubi-Sans G, Palacio C, Torrella JR, Pages T, Ward MD, Viscor G, Petriz J.

Vybrant DyeCycle Violet stain discriminates two different subsets of CD34+ cells. CURR STEM CELL RES T 2016;11(1):66-71.

Article

Impact Factor: 2,645

63 Ocio EM, Oriol A, Bladé J, Teruel AI, Martín J, de la Rubia J, Gutiérrez NC, Rodríguez Díaz-Pavón J, Martínez González S, Coronado C, Fernández-García EM, Siguero Gómez M, Fernández-Teruel C, San Miguel J.

Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma. BRIT J HAEMATOL 2016 Feb;172(4):625-8. doi: 10.1111/bjh.13515. Epub 2015 Jun 2.

Carta

Impact Factor: 5,401

64 Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, Cabrera Marin JR, Espigado I, Solano C, Ferrà C, García- Noblejas A, Jimenez S, Sampol A, Yañez L, García-Gutiérrez V, Pascual MJ, Jurado M, Moraleda JM, Valcarcel D, Sanz MA, Carreras E, Duarte RF.

Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.

BIOL BLOOD MARROW TR 2016 Mar;22(3):584-8. doi: 10.1016/j.bbmt.2015.11.012.

Article

Impact Factor: 3,980

65 Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, Flores-Montero J, Gutierrez NC, Martín-Ramos ML, Martínez-Lopez J, Ocio EM, Hernandez MT, Teruel AI, Rosiñol L, Echeveste MA, Martínez R, Gironella M, Oriol A, Cabrera C, Martín J, Bargay J, Encinas C, Gonzalez Y, Van Dongen JJ, Orfao A, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF.

Minimal residual disease monitoring and immune profiling using second generation flow cytometry in elderly multiple myeloma.

BLOOD 2016 Jun 23;127(25):3165-74. doi: 10.1182/blood-2016-03-705319. Epub 2016 Apr 26.

Article

Impact Factor: 11,841

66 Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, García-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF.

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.

BLOOD 2016 Apr 14;127(15):1896-906. doi: 10.1182/blood-2015-08-665679. Epub 2016 Jan 11

Article

Impact Factor: 11,841



67 Paiva B, Martínez-Lopez J, Corchete LA, Sanchez-Vega B, Rapado I, Puig N, Barrio S, Sanchez ML, Alignani D, Lasa M, García de Coca A, Pardo E, Oriol A, Gonzalez Garcia ME, Escalante F, González-López TJ, Palomera L, Alonso J, Prosper F, Orfao A, Vidriales MB, Mateos MV, Lahuerta JJ, Gutierrez NC, San Miguel JF. Phenotypic, transcriptomic and genomic features of clonal plasma cells in light chain amyloidosis. *BLOOD* 2016 Jun 16;127(24):3035-9. doi: 10.1182/blood-2015-10-673095. Epub 2016 Apr 11.

Article

Impact Factor: 11,841

68 Paiva B, Mateos MV, Sanchez-Abarca LI, Puig N, Vidriales MB, López-Corral L, Corchete LA, Hernandez MT, Bargay J, de Arriba F, De La Rubia J, Teruel AI, Giraldo P, Rosiñol L, Prosper F, Oriol A, Hernández J, Esteves G, Lahuerta JJ, Blade J, Perez-Simon JA, San Miguel JF. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. *BLOOD* 2016 Mar 3;127(9):1151-62. doi: 10.1182/blood-2015-10-662320. Epub 2015 Dec 14.

Article

Impact Factor: 11,841

69 Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martínez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Aguirre X, Prosper F, Martín-Subero JL, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, Miguel JF. Differentiation stage of myeloma plasma cells: biological and clinical significance. *LEUKEMIA* 2016 Sep 16. doi: 10.1038/leu.2016.211. [Epub ahead of print]

Article

Impact Factor: 12,104

70 Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, Coll R, Ademà V, Grau J, Jiménez MJ, Pomares H, Marcé S, Mallo M, Millá F, Alonso E, Sureda A, Gallardo D, Feliu E, Ribera JM, Solé F, Zamora L. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.

*ONCOTARGET* 2016 Aug 30;7(35):57021-57035. doi: 10.18632/oncotarget.10937

Article

Impact Factor: 5,008

71 Palomo L, Xicoy B, Garcia O, Mallo M, Ademà V, Cabezón M, Arnan M, Pomares H, Larrayoz MJ, Calasanz MJ, Maciejewski JP, Huang D, Shih LY, Ogawa S, Cervera J, Such E, Coll R, Grau J, Solé F, Zamora L. Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases.

*AM J HEMATOL* 2016 Feb;91(2):185-92. doi: 10.1002/ajh.24227. Epub 2015 Dec 9.

Article

Impact Factor: 5,000

72 Palomo M, Mir E, Rovira M, Escolar G, Carreras E, Diaz-Ricart M.

What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. *BLOOD* 2016 Mar 31;127(13):1719-27. doi: 10.1182/blood-2015-10-676114.

Article

Impact Factor: 11,841

73 Parody R, López-Corral L, Lopez-Godino O, Martínez C, Martino R, Solano C, Barba P, Caballero D, García-Cadenas I, Piñana JL, Marquez-Malaver FJ, Vazquez L, Esquirol A, Boluda JC, Sanchez-Guijo F, Pérez-Simon JA.



GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.

BONE MARROW TRANSPL 2016 Nov;51(11):1524-1526. doi: 10.1038/bmt.2016.163. No abstract available.

Article

Impact Factor: 3,636

74 Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spandl S, et al.

Time-dependent changes in mortality and transformation risk in MDS. BLOOD 2016 Aug 18;128(7):902-10. doi: 10.1182/blood-2016-02-700054.

Article

Impact Factor: 11,841

75 Piñana JL, Sanz J, Esquirol A, Martino R, Picardi A, Barba P, Parody R, Gayoso J, Montesinos P, Guidi S, Terol MJ, Moscardó F, Solano C, Arcese W, Sanz MA, Sierra J, Sanz G; GETH GITMO groups.

Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.

EUR J HAEMATOL 2016 Feb;96(2):128-35. doi: 10.1111/ejh.12557.

Article

Impact Factor: 2,544

76 Prieto C, Stam RW, Agraz-Doblas A, Ballerini P, Camos M, Castaño J, Marschalek R, Bursen A, Varela I, Bueno C, Menendez P.

Activated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia.

CANCER RES 2016 Apr 15;76(8):2478-89. doi: 10.1158/0008-5472.CAN-15-2769.

Article

Impact Factor: 8,556

77 Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, Ahern J, Khot A, Hein N, George AJ, Hannan KM, Poortinga G, Sheppard KE, Khanna KK, Johnstone RW, Drygin D, McArthur GA, Pearson RB, Sanji E, Hannan RD. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. ONCOTARGET 2016 Aug 2;7(31):49800-49818. doi: 10.18632/oncotarget.10452.

Article

Impact Factor: 5,008

78 Raje NS, Moreau P, Terpos E, Benboubker L, Grząsko N, Holstein SA, Oriol A, Huang SY, Beksac M, Kuliczowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ, Nguyen TS, Cronier DM, Palumbo A.

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.

BRIT J HAEMATOL 2016 Dec 22. doi: 10.1111/bjh.14483. [Epub ahead of print] Article

Impact Factor: 5,401

79 Ramos F, Robledo C, Izquierdo-García FM, Suárez-Vilela D, Benito R, Fuertes M, Insunza A, Barragán E, Del Rey M, de Morales JM, Tormo M, Salido E, Zamora L, Pedro C, Sánchez-Del-Real J, Díez-Campelo M, Del Cañizo C, Sanz GF, Hernández-Rivas JM; Spanish Group for Myelodysplastic Syndromes (GESMD).

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis. ONCOTARGET 2016 May 24;7(21):30492-503. doi: 10.18632/oncotarget.9026.

Article

Impact Factor: 5,008



80 Ribera JM, García O, Oriol A, Gil C, Montesinos P, Bernal T, González-Campos J, Lavilla E, Ribera J, Brunet S, Martínez MP, Tormo M, Genescà E, Barba P, Sarrà J, Monteserín MC, Soria B, Colorado M, Cladera A, García-Guiñón A, Calbacho M, Serrano A, Ortín X, Pedreño M, Amigo ML, Escoda L, Feliu E; PETHEMA Group, Spanish Society of Hematology.

Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.

LEUKEMIA RES 2016 Feb;41:12-20. doi: 10.1016/j.leukres.2015.11.012. Epub 2015 Dec 2.

Article

Impact Factor: 2,606

81 Rico LG, Juncà J, Ward MD, Bradford J, Petriz J.

Is alkaline phosphatase the smoking gun for highly refractory primitive leukemic cells? ONCOTARGET 2016 Nov 1;7(44):72057-72066. doi: 10.18632/oncotarget.12497.

Article

Impact Factor: 5,008

82 Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martín-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, Aldaz B, Vilas-Zornoza A, Zhang S, Moody S, Calasanz MJ, Tousseyn T, Broccardo C, et al.

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

NAT COMMUN 2016 Jun 14;7:11889. doi: 10.1038/ncomms11889.

Article

Impact Factor: 11,329

83 Rousselot P, Coudé MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Salanoubat C, Bonmati C, Alexis M, Hunault M, Glaisner S, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Lafage-Pochitaloff M, Bornand A, Morisset L, Robin V, Pfeifer H, Delannoy A, Ribera J, Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. BLOOD 2016 Aug 11;128(6):774-82. doi: 10.1182/blood-2016-02-700153. Epub 2016 Apr 27.

Article

Impact Factor: 11,841

84 Rueda F, Céspedes MV, Sánchez-Chardi A, Seras-Franzoso J, Pesarrodona M, Ferrer-Miralles N, Vázquez E, Rinas U, Unzueta U, Mamat U, Mangues R, García-Fruitós E, Villaverde A.

Structural and functional features of self-assembling protein nanoparticles produced in endotoxin-free Escherichia coli. MICROB CELL FACT 2016 Apr 8;15:59. doi: 10.1186/s12934-016-0457-z.

Article

Impact Factor: 3,744

85 Sanchez-Garcia L, Martín L, Mangues R, Ferrer-Miralles N, Vázquez E, Villaverde A. Recombinant pharmaceuticals from microbial cells: a 2015 update.

MICROB CELL FACT 2016 Feb 9;15:33. doi: 10.1186/s12934-016-0437-3. Review.

Article

Impact Factor: 3,744

86 Sancho JM, Duarte R, Medina L, Querol S, Marín P, Sureda A; en representación del Grupo de Trabajo de Movilización de la Sociedad Catalana de Hematología y Hemoterapia y de la Sociedad Catalano-Balear de Transfusión Sanguínea. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].

MED CLIN-BARCELONA 2016 Sep 2;147(5):223.e1-7. doi: 10.1016/j.medcli.2016.05.019. Epub 2016 Jun 30.

English Abstract Impact Factor: 1,267



- 87 Sancho JM, Ribera JM; en representación del Grupo de Trabajo sobre Diagnóstico, Prevención y Tratamiento de la Infiltración del SNC en pacientes con LBDCG.  
Central nervous system relapse in diffuse large B cell lymphoma: Risk factors.  
MED CLIN-BARCELONA 2016 Jan 15;146(2):74-80. doi: 10.1016/j.medcli.2014.12.025. Epub 2015 Mar 24.  
Revisio  
Impact Factor: 1,267
- 88 Sanjuan-Pla A, Romero-Moya D, Prieto C, Bueno C, Bigas A, Menendez P.  
Intra-Bone Marrow Transplantation Confers Superior Multilineage Engraftment of Murine Aorta-Gonad Mesonephros Cells Over Intravenous Transplantation.  
STEM CELLS DEV 2016 Feb 1;25(3):259-65. doi: 10.1089/scd.2015.0309.  
Article  
Impact Factor: 3,777
- 89 Sarrate E, Sorigue M, Carbajal M, Portal I, Sancho JM, Juncà J.  
Late isolated intraocular relapse of a systemic diffuse large B-cell lymphoma detected by flow cytometry. ANN HEMATOL 2016 Dec 8. [Epub ahead of print] No abstract available.  
Article  
Impact Factor: 3,022
- 90 Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, Bunjes D, Schaap N, Vigouroux S, Bacigalupo A, Veelken H, Sierra J, Eder M, Niederwieser D, Mohty M, Nagler A.  
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantat...  
J HEMATOL ONCOL 2016 Nov 8;9(1):118.  
Article  
Impact Factor: 6,263
- 91 Sorigue M, Garcia O, Baptista MJ, Sancho JM, Tapia G, Mate JL, Feliu E, Navarro JT, Ribera JM.  
Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.  
MED CLIN-BARCELONA 2016 Dec 27. pii: S0025-7753(16)30611-X. doi: 10.1016/j.medcli.2016.09.050. [Epub ahead of print] English, Spanish. Article  
Impact Factor: 1,267
- 92 Sorigué M, Juncà J, Marcé S, Cabezón M, García O, Zamora L.  
The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies.  
LEUKEMIA LYMPHOMA 2016 Jan;57(1):244-6. doi: 10.3109/10428194.2015.1046865. Epub 2015 Jun 18. No abstract available. Article  
Impact Factor: 3,093
- 93 Sorigué M, Ribera JM, García O, Cabezón M, Vélez P, Marcé S, Xicoy B, Fernández C, Buch J, Cortes M, Plensa E, Gallardo D, Boqué C, Feliu E, Zamora L.  
Highly variable mutational profile of ASXL1 in myelofibrosis.  
EUR J HAEMATOL 2016 Oct;97(4):331-5. doi: 10.1111/ejh.12731. Epub 2016 Jan 19.  
Article  
Impact Factor: 2,544





- 94 Sorigue M, Ribera JM, Motlló C, Sancho JM. New drugs for follicular lymphoma. LEUKEMIA RES 2016 Oct;49:38-46. doi: 10.1016/j.leukres.2016.08.004. Epub 2016 Aug 10. Article  
Impact Factor: 2,606
- 95 Sorigue M, Ribera JM, Sancho JM. The clinical dilemma of grade 3 follicular lymphoma. ANN ONCOL 2016 Oct;27(10):1974. doi: 10.1093/annonc/mdw284. Epub 2016 Aug 8. Article  
Impact Factor: 9,269
- 96 Sorigue M, Sancho JM, García O, Vila J, Moreno M, Ribera JM. [Mantle cell lymphoma, response to treatment and prognosis in 45 patients]. MED CLIN-BARCELONA 2016 Jul 1;147(1):18-21. doi: 10.1016/j.medcli.2016.03.016. Epub 2016 May 6. English Abstract Impact Factor: 1,267
- 97 Sorigue M, Sancho JM, Ribera JM. Open questions in watchful waiting for follicular lymphoma. BRIT J HAEMATOL 2016 Jul 8. doi: 10.1111/bjh.14246. [Epub ahead of print] Carta  
Impact Factor: 5,401
- 98 Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San- Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J CLIN ONCOL 2016 Sep 6. pii: JCO669648. [Epub ahead of print] Article  
Impact Factor: 20,982
- 99 Vazquez E, Mangues R, Villaverde A. Functional recruitment for drug delivery through protein-based nanotechnologies. NANOMEDICINE-UK 2016 Jun;11(11):1333-6. doi: 10.2217/nnm-2016-0090. No abstract available. Article  
Impact Factor: 4,889



### **Headquarters**

C/ Muntaner, 383 3r. 08021  
Barcelona  
Tel. (+34) 93 414 55 66

For any matter concerning this report  
please contact:  
[comunicacio@carrerasresearch.org](mailto:comunicacio@carrerasresearch.org)  
The report can also be downloaded  
from: <http://www.carrerasresearch.org>

### **Publisher, layout and typesetting**

Josep Carreras Leukaemia Research  
Institute

### **Photography**

Photographic archives of the Josep  
Carreras Leukaemia Foundation and  
the Josep Carreras Leukaemia  
Research Institute





**Josep Carreras**  
LEUKAEMIA  
Research Institute